Released: · Last reviewed:
Compounded semaglutide and brand-name semaglutide (Ozempic, Wegovy) are both semaglutide products, but they are distinct products with different FDA status, different pharmacy fulfillment, different prices, and different regulatory protections.
Brand-name advantages: FDA-approved efficacy and safety. Brand-name disadvantages: substantially higher cost; insurance coverage may be limited for weight management. Compounded advantages: substantially lower cost ($95/mo at NexLife vs $1,059/mo retail Wegovy); flat-rate pricing across titration schedule; broader access. Compounded disadvantages: not FDA-approved; quality depends on the compounding pharmacy; subject to evolving FDA enforcement guidance. Both are dispensed by licensed U.S. providers and prescribed by licensed clinicians.
NexLife is structured around clinical best practices for semaglutide. See full NexLife review.
Compounded semaglutide · clinician oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000
Citations supporting clinical and regulatory statements on this page. External links open in a new tab.